Affimed N.V. (0HL9.L)
USD 0.73
(1.12%)
USD 0.73
(1.12%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -102.38 Million EUR | -19.82% |
| 2022 | -81.47 Million EUR | -35.36% |
| 2021 | -64 Million EUR | -86.99% |
| 2020 | -34.22 Million EUR | -10.25% |
| 2019 | -30.97 Million EUR | -64.48% |
| 2018 | -18.87 Million EUR | 30.38% |
| 2017 | -27.26 Million EUR | 14.79% |
| 2016 | -31.1 Million EUR | -46.92% |
| 2015 | -19.2 Million EUR | -166.79% |
| 2014 | -8.11 Million EUR | 46.83% |
| 2013 | -15.26 Million EUR | -52.88% |
| 2012 | -9.98 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -17.06 Million EUR | 13.43% |
| 2024 Q2 | -14.86 Million EUR | 12.08% |
| 2023 Q1 | -30.66 Million EUR | -10.08% |
| 2023 FY | - EUR | -19.82% |
| 2023 Q2 | -28.75 Million EUR | 6.21% |
| 2023 Q4 | -20.82 Million EUR | 11.63% |
| 2023 Q3 | -23.56 Million EUR | 18.06% |
| 2022 FY | - EUR | -35.36% |
| 2022 Q3 | -18.72 Million EUR | 12.2% |
| 2022 Q2 | -21.33 Million EUR | -26.6% |
| 2022 Q1 | -16.84 Million EUR | 29.57% |
| 2022 Q4 | -27.85 Million EUR | -48.73% |
| 2021 FY | - EUR | -86.99% |
| 2021 Q1 | -3.79 Million EUR | 53.21% |
| 2021 Q2 | -17.02 Million EUR | -349.08% |
| 2021 Q3 | -18.37 Million EUR | -7.87% |
| 2021 Q4 | -23.92 Million EUR | -30.21% |
| 2020 Q4 | -8.1 Million EUR | -209.59% |
| 2020 FY | - EUR | -10.25% |
| 2020 Q3 | -2.61 Million EUR | 76.07% |
| 2020 Q2 | -10.94 Million EUR | -14.92% |
| 2020 Q1 | -9.52 Million EUR | 15.47% |
| 2019 Q3 | -11.97 Million EUR | -29.25% |
| 2019 Q2 | -9.26 Million EUR | -731.7% |
| 2019 FY | - EUR | -64.48% |
| 2019 Q1 | 1.46 Million EUR | -85.11% |
| 2019 Q4 | -11.26 Million EUR | 5.96% |
| 2018 Q4 | 9.85 Million EUR | 182.27% |
| 2018 Q1 | -7.78 Million EUR | -34.85% |
| 2018 FY | - EUR | 30.38% |
| 2018 Q3 | -11.97 Million EUR | -33.52% |
| 2018 Q2 | -8.96 Million EUR | -15.21% |
| 2017 Q2 | -6.7 Million EUR | 6.6% |
| 2017 Q3 | -7.19 Million EUR | -7.26% |
| 2017 Q4 | -5.77 Million EUR | 19.74% |
| 2017 Q1 | -7.18 Million EUR | -12.88% |
| 2017 FY | - EUR | 14.79% |
| 2016 Q2 | -8.36 Million EUR | -19.0% |
| 2016 FY | - EUR | -46.92% |
| 2016 Q1 | -7.02 Million EUR | 2.9% |
| 2016 Q4 | -6.36 Million EUR | 35.43% |
| 2016 Q3 | -9.85 Million EUR | -17.85% |
| 2015 Q3 | -6.99 Million EUR | -43.31% |
| 2015 Q4 | -7.23 Million EUR | -3.48% |
| 2015 Q2 | -4.87 Million EUR | -154.38% |
| 2015 Q1 | -1.91 Million EUR | 66.17% |
| 2015 FY | - EUR | -166.79% |
| 2014 FY | - EUR | 46.83% |
| 2014 Q1 | -9.25 Million EUR | -307.12% |
| 2014 Q2 | 7.23 Million EUR | 178.19% |
| 2014 Q3 | 437 Thousand EUR | -93.96% |
| 2014 Q4 | -5.66 Million EUR | -1397.25% |
| 2013 Q1 | -2.64 Million EUR | 0.0% |
| 2013 Q4 | 4.46 Million EUR | 170.63% |
| 2013 Q2 | -5.42 Million EUR | -105.06% |
| 2013 FY | - EUR | -52.88% |
| 2013 Q3 | -6.32 Million EUR | -16.54% |
| 2012 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| uniQure N.V. | -253.1 Million USD | 59.55% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -102.444% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -16.361% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 106.105% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 70.365% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | 55.12% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -11.187% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -83.621% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 61.511% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 54.496% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 132.996% |
| bluebird bio, Inc. | -167.16 Million USD | 38.754% |
| Blueprint Medicines Corporation | -474.61 Million USD | 78.429% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 12.979% |
| Imunon, Inc. | -20.78 Million USD | -392.631% |
| Adicet Bio, Inc. | -136.53 Million USD | 25.016% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 194.513% |
| Dynavax Technologies Corporation | 9.66 Million USD | 1159.176% |
| Editas Medicine, Inc. | -163.11 Million USD | 37.235% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 79.739% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 31.796% |
| Exelixis, Inc. | 196.6 Million USD | 152.075% |
| FibroGen, Inc. | -261.4 Million USD | 60.835% |
| Geron Corporation | -174.78 Million USD | 41.424% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 122.653% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 1.36% |
| Illumina, Inc. | -608 Million USD | 83.161% |
| Incyte Corporation | 919.42 Million USD | 111.135% |
| Insmed Incorporated | -654.73 Million USD | 84.363% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 79.779% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 55.489% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 77.199% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 103.144% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -183.743% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 108.795% |
| Evolus, Inc. | -41.81 Million USD | -144.87% |
| Myriad Genetics, Inc. | -67.8 Million USD | -51.003% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 124.605% |
| OPKO Health, Inc. | -65.51 Million USD | -56.267% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 76.689% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 204.191% |
| Verastem, Inc. | -83.16 Million USD | -23.103% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 99.092% |
| Waters Corporation | 1.02 Billion USD | 110.015% |
| Zoetis Inc. | 3.68 Billion USD | 102.778% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 102.223% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 100.948% |
| Biogen Inc. | 2.37 Billion USD | 104.307% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -17.103% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.2% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -130.395% |
| Homology Medicines, Inc. | -47.75 Million USD | -114.381% |
| Nektar Therapeutics | -243.1 Million USD | 57.887% |
| TG Therapeutics, Inc. | 26.1 Million USD | 492.261% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -1.54% |
| Perrigo Company plc | 646.2 Million USD | 115.843% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -174.602% |